Invitrogen to Acquire Molecular Probes for $325M — Six Times Revenue

Invitrogen has bought privately held Molecular Probes for $325 million in cash — a whopping six times what the company earned in sales last year.

With the sale, expected to close during the current quarter, Invitrogen hopes to position itself in the drug-discovery and -development sector, CEO Greg Lucier said in a statement.

Molecular Probes, of Eugene, Ore., makes and sells fluorescence-based technologies. The company was founded in 1975, and had $56 million in revenues in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.